OncoSil Medical Limited (ASX:OSL) has advised that the time of its presentation at the Bell Potter Healthcare Conference 2026 has changed to Thursday, 19 November 2026, at 4:00 pm AEDT, updating a previous notice issued on 16 November 2026.

Key Points

  • Presentation time updated to 4:00 pm AEDT on Thursday, 19 November 2026 (Session 4)
  • CEO and Managing Director Mr Nigel Lange will present on behalf of the company
  • The presentation will be delivered virtually via Bell Potter Client Access
  • The update refers to an earlier notice issued by OncoSil Medical on 16 November 2026

Updated Presentation Time at Bell Potter Healthcare Conference 2026

OncoSil Medical Limited disclosed on 19 November 2026 that the time of its presentation at the Bell Potter Healthcare Conference 2026 has been revised. The presentation is now scheduled for Thursday, 19 November 2026, at 4:00 pm AEDT, designated as Session 4. This update supersedes the timing disclosed in the company's earlier notice dated 16 November 2026, which had also confirmed the company's participation in the conference. The filing does not disclose any change to the presenter or the format of the session.

Presenter and Virtual Format Details

Mr Nigel Lange, CEO and Managing Director of OncoSil Medical, is named as the presenter for the session. The conference will be conducted virtually and made available exclusively via Bell Potter Client Access, an online platform for Bell Potter clients. According to the filing, investors with an existing Client Access account can view the presentation by logging in and selecting the Healthcare Conference 2026 tab in the top navigation. The filing states that further information, including the conference schedule, is available on the Bell Potter website.

About OncoSil Medical and Its Device

OncoSil Medical is a global medical device company focused on interventional oncology. The company has developed OncoSil™, a single-use brachytherapy device that delivers beta radiation using Phosphorous-32 Microparticles directly into cancerous tissue. OncoSil™ holds CE Marking approval in the European Union and the United Kingdom, and has received approval from the U.S. Food and Drug Administration under a Humanitarian Device Exemption for the treatment of unresectable, non-metastatic distal cholangiocarcinoma as an adjunct to systemic therapy. The device is currently approved for sale in more than 30 countries, according to the filing.